129 related articles for article (PubMed ID: 16317101)
1. Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase and cathepsin G.
Schiemann F; Grimm TA; Hoch J; Gross R; Lindner B; Petersen F; Bulfone-Paus S; Brandt E
Blood; 2006 Mar; 107(6):2234-42. PubMed ID: 16317101
[TBL] [Abstract][Full Text] [Related]
2. Platelet-derived chemokines CXC chemokine ligand (CXCL)7, connective tissue-activating peptide III, and CXCL4 differentially affect and cross-regulate neutrophil adhesion and transendothelial migration.
Schenk BI; Petersen F; Flad HD; Brandt E
J Immunol; 2002 Sep; 169(5):2602-10. PubMed ID: 12193731
[TBL] [Abstract][Full Text] [Related]
3. Formation of neutrophil-activating peptide 2 from platelet-derived connective-tissue-activating peptide III by different tissue proteinases.
Car BD; Baggiolini M; Walz A
Biochem J; 1991 May; 275 ( Pt 3)(Pt 3):581-4. PubMed ID: 2039437
[TBL] [Abstract][Full Text] [Related]
4. Neutrophils can generate their activator neutrophil-activating peptide 2 by proteolytic cleavage of platelet-derived connective tissue-activating peptide III.
Brandt E; Van Damme J; Flad HD
Cytokine; 1991 Jul; 3(4):311-21. PubMed ID: 1873479
[TBL] [Abstract][Full Text] [Related]
5. Chemotactic activity and receptor binding of neutrophil attractant/activation protein-1 (NAP-1) and structurally related host defense cytokines: interaction of NAP-2 with the NAP-1 receptor.
Leonard EJ; Yoshimura T; Rot A; Noer K; Walz A; Baggiolini M; Walz DA; Goetzl EJ; Castor CW
J Leukoc Biol; 1991 Mar; 49(3):258-65. PubMed ID: 1997632
[TBL] [Abstract][Full Text] [Related]
6. Connective tissue-activating peptide III desensitizes chemokine receptors on neutrophils. Requirement for proteolytic formation of the neutrophil-activating peptide 2.
Härter L; Petersen F; Flad HD; Brandt E
J Immunol; 1994 Dec; 153(12):5698-708. PubMed ID: 7989767
[TBL] [Abstract][Full Text] [Related]
7. Generation of the neutrophil-activating peptide-2 by cathepsin G and cathepsin G-treated human platelets.
Cohen AB; Stevens MD; Miller EJ; Atkinson MA; Mullenbach G
Am J Physiol; 1992 Aug; 263(2 Pt 1):L249-56. PubMed ID: 1387511
[TBL] [Abstract][Full Text] [Related]
8. Identification of a cathepsin G-like proteinase in the MCTC type of human mast cell.
Schechter NM; Irani AM; Sprows JL; Abernethy J; Wintroub B; Schwartz LB
J Immunol; 1990 Oct; 145(8):2652-61. PubMed ID: 2212656
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of neutrophil functions by the ELR(+) CXC chemokine platelet basic protein.
Ehlert JE; Ludwig A; Grimm TA; Lindner B; Flad HD; Brandt E
Blood; 2000 Nov; 96(9):2965-72. PubMed ID: 11049972
[TBL] [Abstract][Full Text] [Related]
10. Determination of the primary structures of human skin chymase and cathepsin G from cutaneous mast cells of urticaria pigmentosa lesions.
Schechter NM; Wang ZM; Blacher RW; Lessin SR; Lazarus GS; Rubin H
J Immunol; 1994 Apr; 152(8):4062-9. PubMed ID: 8144971
[TBL] [Abstract][Full Text] [Related]
11. Interference of neutrophil-platelet interaction by YC-1: a cGMP-dependent manner on heterotypic cell-cell interaction.
Liao CH; Cheng JT; Teng CM
Eur J Pharmacol; 2005 Sep; 519(1-2):158-67. PubMed ID: 16112105
[TBL] [Abstract][Full Text] [Related]
12. A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo.
de Garavilla L; Greco MN; Sukumar N; Chen ZW; Pineda AO; Mathews FS; Di Cera E; Giardino EC; Wells GI; Haertlein BJ; Kauffman JA; Corcoran TW; Derian CK; Eckardt AJ; Damiano BP; Andrade-Gordon P; Maryanoff BE
J Biol Chem; 2005 May; 280(18):18001-7. PubMed ID: 15741158
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of substance P and bradykinin by human neutrophils.
Skidgel RA; Jackman HL; Erdös EG
Biochem Pharmacol; 1991 May; 41(9):1335-44. PubMed ID: 1708255
[TBL] [Abstract][Full Text] [Related]
14. Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils.
Walz A; Dewald B; von Tscharner V; Baggiolini M
J Exp Med; 1989 Nov; 170(5):1745-50. PubMed ID: 2681518
[TBL] [Abstract][Full Text] [Related]
15. Inducible binding of bioactive cathepsin G to the cell surface of neutrophils. A novel mechanism for mediating extracellular catalytic activity of cathepsin G.
Owen CA; Campbell MA; Boukedes SS; Campbell EJ
J Immunol; 1995 Dec; 155(12):5803-10. PubMed ID: 7499869
[TBL] [Abstract][Full Text] [Related]
16. The inhibition of mast cell activation by neutrophil lactoferrin: uptake by mast cells and interaction with tryptase, chymase and cathepsin G.
He S; McEuen AR; Blewett SA; Li P; Buckley MG; Leufkens P; Walls AF
Biochem Pharmacol; 2003 Mar; 65(6):1007-15. PubMed ID: 12623133
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin I conversion by human and rat chymotryptic proteinases.
Wintroub BU; Schechter NB; Lazarus GS; Kaempfer CE; Schwartz LB
J Invest Dermatol; 1984 Nov; 83(5):336-9. PubMed ID: 6092480
[TBL] [Abstract][Full Text] [Related]
18. The beta-thromboglobulins and platelet factor 4: blood platelet-derived CXC chemokines with divergent roles in early neutrophil regulation.
Brandt E; Petersen F; Ludwig A; Ehlert JE; Bock L; Flad HD
J Leukoc Biol; 2000 Apr; 67(4):471-8. PubMed ID: 10770278
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of chymase as mast cell-stabilizing agents: contribution of chymase in the activation of human mast cells.
He S; Gaça MD; McEuen AR; Walls AF
J Pharmacol Exp Ther; 1999 Nov; 291(2):517-23. PubMed ID: 10525066
[TBL] [Abstract][Full Text] [Related]
20. Relationship between neutrophil-binding affinity and suitability for infection imaging: comparison of (99m)Tc-labeled NAP-2 (CXCL-7) and 3 C-terminally truncated isoforms.
Rennen HJ; Frielink C; Brandt E; Zaat SA; Boerman OC; Oyen WJ; Corstens FH
J Nucl Med; 2004 Jul; 45(7):1217-23. PubMed ID: 15235069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
